The percentage of new claimants taking Brenzys or Erelzi, biosimilars for Enbrel, has quadrupled in the past year, climbing to 31 per cent from eight per cent, according to the latest claims data from TELUS Health. This translates into 21% of eligible costs for new claimants, up from four per cent (see chart). Grastofil, a biosimilar for Neupogen, has doubled to reach 51 per cent of new claimants and 47 per cent of new-claimant eligible costs. Its relatively high market share is in part due to the fact that the drug is typically used as an acute therapy, which means that the usual issues around switching do not apply. All patients are essentially "new" patients. Last but not least, Inflectra, the first major biosimilar in Canada (for Remicade, the country's top drug by revenue) is slowly making inroads. The percentage…
To read this article you must be logged in
We will use your email address to send you our newsletter. All communications will be from TELUS Health.
We will use your email address to send you our newsletter.
All communications will be from TELUS Health.
All fields are required